EP0937095A4 - Targeted cytolysis of cancer cells - Google Patents

Targeted cytolysis of cancer cells

Info

Publication number
EP0937095A4
EP0937095A4 EP97911757A EP97911757A EP0937095A4 EP 0937095 A4 EP0937095 A4 EP 0937095A4 EP 97911757 A EP97911757 A EP 97911757A EP 97911757 A EP97911757 A EP 97911757A EP 0937095 A4 EP0937095 A4 EP 0937095A4
Authority
EP
European Patent Office
Prior art keywords
cancer cells
cytolysis
targeted
targeted cytolysis
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97911757A
Other languages
German (de)
French (fr)
Other versions
EP0937095A1 (en
Inventor
Gary B Greenburg
James G Mcarthur
Mitchell H Finer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Genesys Inc
Original Assignee
Cell Genesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Genesys Inc filed Critical Cell Genesys Inc
Publication of EP0937095A1 publication Critical patent/EP0937095A1/en
Publication of EP0937095A4 publication Critical patent/EP0937095A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP97911757A 1996-10-25 1997-10-24 Targeted cytolysis of cancer cells Withdrawn EP0937095A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2902996P 1996-10-25 1996-10-25
US29029P 1996-10-25
PCT/US1997/018707 WO1998018809A1 (en) 1996-10-25 1997-10-24 Targeted cytolysis of cancer cells

Publications (2)

Publication Number Publication Date
EP0937095A1 EP0937095A1 (en) 1999-08-25
EP0937095A4 true EP0937095A4 (en) 1999-12-22

Family

ID=21846848

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97911757A Withdrawn EP0937095A4 (en) 1996-10-25 1997-10-24 Targeted cytolysis of cancer cells

Country Status (5)

Country Link
EP (1) EP0937095A4 (en)
JP (1) JP2002512502A (en)
AU (1) AU744160B2 (en)
CA (1) CA2269738A1 (en)
WO (1) WO1998018809A1 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
KR20020073127A (en) * 1999-09-17 2002-09-19 겐자임 트랜스제닉스 코포레이션 Transgenically produced fusion proteins
EP1532162B1 (en) 2002-06-28 2013-08-07 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
US7589181B2 (en) 2003-08-29 2009-09-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US12492376B2 (en) 2009-10-29 2025-12-09 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
CA2789446A1 (en) 2010-02-12 2011-08-18 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
ES2719495T5 (en) 2012-05-07 2025-09-10 Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
LT2958943T (en) 2013-02-20 2020-01-27 The Trustees Of The University Of Pennsylvania CANCER TREATMENT USING HUMANIZED ANTI-EGFRVIII CHIMERY ANTIGEN RECEPTOR
US9573988B2 (en) 2013-02-20 2017-02-21 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
EP2970426B1 (en) 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
TWI654206B (en) 2013-03-16 2019-03-21 諾華公司 Treatment of cancer with a humanized anti-CD19 chimeric antigen receptor
CA2954168C (en) * 2013-08-02 2023-09-19 The Regents Of The University Of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
CA2931684C (en) 2013-12-19 2024-02-20 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
WO2015112626A1 (en) 2014-01-21 2015-07-30 June Carl H Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
IL322264A (en) 2014-04-07 2025-09-01 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
MY181834A (en) 2014-07-21 2021-01-08 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
US9777061B2 (en) 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
SG11201700770PA (en) 2014-08-19 2017-03-30 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
ES2891332T3 (en) 2014-09-17 2022-01-27 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
AU2015330898B2 (en) 2014-10-08 2022-03-10 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
CN107567461A (en) 2014-12-29 2018-01-09 诺华股份有限公司 The method for preparing Chimeric antigen receptor expression cell
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
MX2017012939A (en) 2015-04-08 2018-05-22 Novartis Ag CD20 THERAPIES, CD22 THERAPIES AND COMBINATION THERAPIES WITH A CELL THAT EXPRESSES AN ANTIGEN (CAR) CHEMICAL RECEIVER OF CD19.
AU2016249005B2 (en) 2015-04-17 2022-06-16 Novartis Ag Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
WO2017015427A1 (en) 2015-07-21 2017-01-26 Novartis Ag Methods for improving the efficacy and expansion of immune cells
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
CN116334205A (en) 2015-09-03 2023-06-27 诺华股份有限公司 Biomarkers predictive of cytokine release syndrome
ES2862907T3 (en) * 2015-11-27 2021-10-08 Cartherics Pty Ltd Genetically modified cells and their uses
CN108699557B (en) 2015-12-04 2025-08-15 诺华股份有限公司 Compositions and methods for immunooncology
PT3393504T (en) 2015-12-22 2025-12-30 Novartis Ag Mesothelin chimeric antigen receptor (CAR) and anti-PD-L1 inhibitor antibody for combined use in anticancer therapy.
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
WO2018067992A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
EP3574005B1 (en) 2017-01-26 2021-12-15 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
KR20190130608A (en) 2017-03-22 2019-11-22 노파르티스 아게 Compositions and Methods for Immune Oncology
KR20200086278A (en) 2017-10-18 2020-07-16 노파르티스 아게 Compositions and methods for selective proteolysis
CN112218651A (en) 2018-01-08 2021-01-12 诺华公司 Immunopotentiating RNA for combination with chimeric antigen receptor therapy
CN111727058A (en) * 2018-02-23 2020-09-29 卡瑟里克斯私人有限公司 T-cell disease therapy targeting TAG-72
AU2019284911B2 (en) 2018-06-13 2026-04-09 Novartis Ag BCMA chimeric antigen receptors and uses thereof
EP4065158A2 (en) 2019-11-26 2022-10-05 Novartis AG Chimeric antigen receptors binding bcma and cd19 and uses thereof
KR20220104217A (en) 2019-11-26 2022-07-26 노파르티스 아게 CD19 and CD22 chimeric antigen receptors and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359046A (en) * 1990-12-14 1994-10-25 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103521A (en) * 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359046A (en) * 1990-12-14 1994-10-25 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ESHHAR ET AL: "SPECIFIC ACTIVATION AND TARGETING OF CYTOTOXIC LYMPHOCYTES THROUGH CHIMERIC SINGLE CHAINS CONSISTING OF ANTIBODY-BINDING DOMAINS AND THE GAMMA OR ZETA SUBUNITS OF THE IMMUNOGLOBULIN AND T-CELL RECEPTORS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 90, 1 January 1993 (1993-01-01), pages 720 - 724, XP002088319 *
HOMBACH A ET AL: "T cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope.", GASTROENTEROLOGY, (1997 OCT) 113 (4) 1163-70. JOURNAL CODE: FH3. ISSN: 0016-5085., United States, XP002117237 *
HOMBACH, A. ET AL: "Expression of functional active chimeric T-cell receptors with antibody like specificity for the TAG72 tumor antigen.", ANNALS OF HEMATOLOGY, (1996) VOL. 73, NO. SUPPL. 2, PP. A152. MEETING INFO.: ANNUAL CONGRESS OF THE GERMAN AND THE AUSTRIAN SOCIETY OF HEMATOLOGY AND ONCOLOGY DUESSELDORF, GERMANY OCTOBER 3-7, 1996 ISSN: 0939-5555., XP002117385 *
MCARTHUR, J. G. (1) ET AL: "Targeting of tumor cells by T cells transduced with TAG-72 tumor antigen specific MHC-unrestricted chimeric T cell receptors.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (1997) VOL. 38, NO. 0, PP. 37. MEETING INFO.: EIGHTY-EIGHTH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH SAN DIEGO, CALIFORNIA, USA APRIL 12-16, 1997 ISSN:, XP002117386 *
MCGUINNESS R P ET AL: "Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor [see comments].", HUMAN GENE THERAPY, (1999 JAN 20) 10 (2) 165-73. JOURNAL CODE: A12. ISSN: 1043-0342., United States, XP002117239 *
MCGUINNESS, R. ET AL: "Targeting of tumor cells by T lymphocytes expressing tumor associated antigen specific, MHC-unrestricted chimeric T cell receptors.", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, (1997) VOL. 99, NO. 1 PART 2, PP. S41. MEETING INFO.: JOINT MEETING OF THE AM. ACAD. OF ALLERGY, ASTHMA AND IMMUNOL., THE AM. ASSOC. OF IMMUNOL. AND THE CLIN. IMMUNOL. SOC. SAN FRANSCISCO, FEBR. 21-26, 1997, XP002117387 *
SCHLOM, J. ET AL.: "Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates", CANCER RESEARCH, vol. 52, 1 March 1992 (1992-03-01), pages 1067 - 1072, XP002117238 *
See also references of WO9818809A1 *

Also Published As

Publication number Publication date
JP2002512502A (en) 2002-04-23
EP0937095A1 (en) 1999-08-25
CA2269738A1 (en) 1998-05-07
AU744160B2 (en) 2002-02-14
AU4905897A (en) 1998-05-22
WO1998018809A1 (en) 1998-05-07

Similar Documents

Publication Publication Date Title
GB9622500D0 (en) Therapeutic gene
ZA972494B (en) Long wearing lipstick
EP0934404A4 (en) Inhibition of proliferation of cells
AU3583797A (en) Enhancement of cancer cell death
HUP9702242A3 (en) Inozitol-glykanes of inzulin-like activity
EP0972830A4 (en) Cancer-associated genes
AU6537798A (en) Targeted cytolysis of cancer cells
GB9602704D0 (en) Structure of perculator
GB9605453D0 (en) Cultured cells
IL129474A0 (en) Targeted cytotoxic cells
PL328829A1 (en) Enzyme
PL313849A1 (en) Beta-aminoesters of o-hydrobenzylamides
AU1801499A (en) Uses of p27 in prostate cancer
GB2333527B (en) Therapeutic gene
TW312301U (en) Improved structure of earmask
TW319017U (en) Improved structure of mousetraps
GB9713139D0 (en) Use of enzymes
GB9621289D0 (en) Pond
GB9617709D0 (en) Enzyme
GB9723412D0 (en) Cancer gene
TW309212U (en) Runner system of fuel cell
TW304520U (en) Improved structure of groyne
GB9727347D0 (en) Cancer
AP9600848A0 (en) Ther peuti amid s
TW301421U (en) Improved structure of rotaion-type calculator

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990422

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19991104

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20020910